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Summary
Calcium homeostasis by the kidneys and parathyroids
is mediated by the calcium-sensing receptor (CaSR),
which is located on 3q21-q24 and belongs to family C
of the superfamily of G-protein coupled receptors that
includes those for metabotropic glutamate, certain pher-
omones, and g-amino butyric acid (GABA-B). Inacti-
vating CaSR mutations result in familial benign hyper-
calcemia (FBH), or familial hypocalciuric hypercalcemia
(FHH), whereas activating mutations result in hypocal-
cemic hypercalciuria. However, not all FBH patients
have CaSR mutations, which, together with the mapping
of another FBH locus to 19p13.3, suggests that addi-
tional CaSRs or second messengers may be involved.
These may be identified by positional cloning, and we
therefore performed a genomewide search, using chro-
mosome-specific sets of microsatellite polymorphisms, in
an Oklahoma family with an FBH variant (FBHOk), for
which linkage to 3q and 19p had been excluded. Linkage
was established between FBHOk and eight chromosome
19q13 loci, with the highest LOD score, 6.67 (recom-
bination fraction .00), obtained with D19S606. Recom-
binants further mapped FBHOk to a !12-cM interval
flanked by D19S908 and D19S866. The calmodulin III
gene is located within this interval, and DNA sequence
analysis of the coding region, the 5′ UTR, and part of
the promoter region in an individual affected with
FBHOk did not detect any abnormalities, thereby indi-
cating that this gene is unlikely to be implicated in the
etiology of FBHOk. This mapping of FBHOk to chro-
mosome 19q13 will facilitate the identification of an-
other CaSR or a mediator of calcium homeostasis.
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Introduction
Familial benign hypercalcemia4 (FBH; MIM 145980) is
a heritable disorder of mineral metabolism that is trans-
mitted as an autosomal dominant trait with a high de-
gree of penetrance (Chou et al. 1992; Brown 1997; He-
bert et al. 1997). FBH is biochemically characterized by
a lifelong elevation of serum calcium concentrations and
is associated with inappropriately low urinary calcium
excretion and, usually, a normal circulating parathyroid
hormone (PTH) concentration (Brown 1997; McKusick
1998). Hypermagnesemia is also typically present. The
disorder is considered to be benign, since patients with
FBH are usually asymptomatic. However, an increased
prevalence of chondrocalcinosis and possibly of pancre-
atitis (Pearce et al. 1996a) has been observed in adults,
and some children may suffer from neonatal severe pri-
mary hyperparathyroidism (NSHPT), a life-threatening
disorder associated with severe hypercalcemia, hypo-
tonia, bone demineralization, fractures, and respiratory
distress (Pollak et al. 1993; Pearce et al. 1995; Bai et al.
1997). The genetic abnormalities causing FBH and
NSHPT in some patients involve loss-of-function mu-
tations of the calcium-sensing receptor (CaSR) located
on chromosome 3q21-q24; these FBH patients are het-
erozygous (wild type/mutant) for the CaSR mutations,
and the NSHPT patients either may be homozygous for
the CaSR mutations or have de novo heterozygous CaSR
4 Familial benign hypercalcemia (FBH) has also been referred to as
“familial hypocalciuric hypercalcemia” (FHH), “familial benign hy-
pocalciuric hypercalcemia” (FBHH), “familial hypercalcemia,” and
“hypocalciuric hypercalcemia, familial” (HHC). In addition, three
types of FBH are recognized: FBH1 (MIM 145980), FBH2 (MIM
145981), and FBH3 (MIM 600740) (or HHC1, HHC2, and HHC3,
respectively; McKusick 1998). FBH3 is also referred to as “hypercal-
cemia, familial benign, Oklahoma type,” “FBH, Oklahoma variant,”
or “FBHOk.” The chromosomal locations of FBH1, FBH2, and FBH3
are 3q21-q24 (Chou et al. 1992), 19p13.3 (Heath et al. 1993), and
19q13 (this report), respectively. Neonatal severe primary hyperpar-
athyroidism (NSHPT), which is also referred to as “neonatal severe
hyperparathyroidism” (NSH), may arise in some families with FBH1
and represents a homozygous manifestation of the benign heterozygous
disorder.
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mutations. The great diversity of the reported CaSR mu-
tations in FBH and NSHPT—which include nonsense,
missense, deletion, and insertion mutations—together
with their scattered locations throughout the 3,234-bp
coding region (Brown 1997), have made it difficult to
establish the use of CaSR-mutation analysis as a method
for the diagnosis of these disorders (Chou et al. 1992;
Pollak et al. 1993; Pearce et al. 1995, 1996b; Bai et al.
1997).
The human CaSR is a 1,078–amino acid cell-surface
protein that is expressed in the parathyroids and kidneys,
where it allows regulation of PTH secretion and renal
tubular calcium reabsorption appropriate to the pre-
vailing extracellular calcium ([Ca2]o) concentration
(Brown 1997; McKusick 1998). The CaSR is a member
of family C of the superfamily of G-protein coupled
receptors (GPCRs) that includes the metabotropic glu-
tamate receptors, some pheromone receptors, and the
g-amino butyric acid (GABA-B) receptors (Birnbaumer
1995; Brown 1997; Hebert et al. 1997). Ligand binding
by the CaSR results in G-protein–dependent stimulation
of phospholipase C (PLC) activity, causing accumulation
of inositol 1,4,5-triphosphate (IP3) and the rapid release
of calcium ions from intracellular stores ([Ca2]i), fol-
lowed by an influx of [Ca2]o (Pearce et al. 1996b; Bai
et al. 1997; Brown 1997; Hebert et al. 1997). These
intracellular events are thought to mediate a decrease in
the rate of PTH secretion from the parathyroid cell and
a reduction in renal tubular calcium reabsorption. Thus,
the CaSR plays a key role in the regulation of extracel-
lular calcium homeostasis, with loss-of-function muta-
tions resulting in the hypocalciuric hypercalcemia of
FBH and gain-of-function mutations resulting in the op-
posite phenotype, hypercalciuria with hypocalcemia
(Pollak et al. 1993, 1994; Pearce et al. 1995, 1996c;
Brown 1997; Hebert et al. 1997). However, such mu-
tations involving the 3,234-bp coding region of the
CaSR gene have been found only in one-half to two-
thirds of FBH patients. Thus, it appears likely that other
mutations involving the as-yet-uncharacterized regions
of the CaSR gene, which include the untranslated, per-
igenic, and distant regulatory regions, or mutations in-
volving other receptors and mediators of calcium reg-
ulation may occur in FBH patients.
The identification of two other FBH loci not linked
to chromosome 3q21-24 indicates genetic heterogeneity
and supports the possibility that there may be additional
CaSRs or second messengers involved in calcium ho-
meostasis. Of these two FBH loci, one has been mapped
to chromosome 19p13.3 (Heath et al. 1993), and the
other—identified in an extensive Oklahoma kindred
with an FBH type called “FBH, Oklahoma variant”
(FBHOk; McMurtry et al. 1992)—has been excluded
from chromosomes 3q and 19p13.3, by linkage analysis
(Trump et al. 1995). The FBHOk kindred is notable for
additional clinical features that arise in some adults as
they age; these features include elevations in serum PTH
concentrations, hypophosphatemia, and osteomalacia
(McMurtry et al. 1992). In order to identify the location
of the FBHOk locus, we undertook a genomewide search
using the available 254 microsatellite polymorphisms in
chromosome-specific sets, with an average intermarker
distance of 13 cM (Reed et al. 1994).
Patients and Methods
Patients
Thirty-eight members, from five generations, of the
previously reported (McMurtry et al. 1992; Trump et
al. 1995) Oklahoma kindred with autosomal dominant
FBH and developmental increases in serum PTH levels
were investigated. For these family members, the bio-
chemical phenotype of FBH was established (McMurtry
et al. 1992; Trump et al. 1995) by documenting hyper-
calcemia associated with a low ratio (!.010) of calcium
clearance to creatinine clearance. Supranormal concen-
trations of serum PTH had been observed in some af-
fected individuals 130 years of age (II-2, II-4, II-6, II-9,
and III-6). Three adults 140 years of age (II-4, II-9, and
III-3) also showed evidence of osteomalacia. An indi-
vidual taking anticonvulsants that may alter Ca2 ho-
meostasis, an individual (IV-4) described previously
(McMurtry et al. 1992) as suffering from hypocalcemia
due to hypoparathyroidism, and four individuals who
were normocalcemic children of unaffected parents were
excluded from the linkage study; the haplotypes of in-
dividual IV-4 were determined but were not included for
analysis at the FBHOk locus. Thus, the 32 family mem-
bers, from four generations, included for genetic analy-
sis of the FBHOk locus consisted of 17 affected mem-
bers, 13 unaffected members, and 2 unaffected spouses
(fig. 1).
Genotyping and Linkage Analysis
Leukocyte DNA was prepared from venous blood
samples, by standard methods (Thakker et al. 1990),
from 33 members (17 affected and 16 unaffected) of the
four-generation FBHOk family (fig. 1). Genomewide link-
age analysis was performed by use of chromosome-spe-
cific sets of fluorescently labeled primers (Oswel DNA
Service; Reed et al. 1994) that identified 254 polymor-
phic microsatellites, 80% of which were derived from
the Ge´ne´thon genetic linkage map and were arranged
into 39 sets covering all 22 autosomes and the X chro-
mosome, with an average intermarker distance of 13 cM
(Gyapay et al. 1994; Reed et al. 1994; Ashworth et al.
1995). Additional markers from chromosome 19 were
also obtained from the Ge´ne´thon linkage map (Gyapay
et al. 1994). PCRs were performed in a total volume of
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Table 1
Two-Point Linkage Analysis between FBHOk and 17 Loci from Chromosome 19
LOCUS
PEAK LOD
SCORE (v)
LOD SCORE AT v a
DISTANCEb
(cM).00 .001 .01 .05 .10 .15 .20
D19S221 .28 (.657) 31.41 17.13 12.77 7.31 4.79 3.36 2.39 35.5
D19S49 .61 (.309) 20.03 10.22 5.57 2.12 .74 .05 .34 ?
D19S225 2.74 (.122) 11.52 2.31 .61 2.32 2.71 2.71 2.53 55.9
D19S220 4.45 (.075) 9.47 1.52 3.42 4.38 4.41 4.16 3.77 61.4
D19S913 3.27 (.093) 3.69 .15 2.08 3.12 3.27 3.13 2.87 67.1
D19S908 4.38 (.046) 1.80 3.14 4.05 4.38 4.19 3.86 3.44 69.2
D19S412 2.53 (.000) 2.53 2.52 2.48 2.32 2.09 1.86 1.61 69.9
D19S219 4.11 (.000) 4.11 4.10 4.05 3.78 3.44 3.07 2.69 69.9
D19S606 6.67 (.000) 6.67 6.65 6.56 6.12 5.56 4.96 4.34 76.2
D19S902 4.31 (.000) 4.31 4.30 4.24 3.95 3.58 3.19 2.78 76.2
D19S879 4.56 (.000) 4.56 4.55 4.49 4.22 3.86 3.48 3.08 78.9
D19S604 5.37 (.000) 5.37 5.36 5.28 4.93 4.47 3.98 3.48 79.0
D19S866 2.20 (.120) 10.16 1.17 .78 1.92 2.18 2.17 2.03 81.1
D19S907 2.60 (.101) 3.82 .23 1.51 2.43 2.60 2.51 2.31 81.7
D19S572 2.49 (.157) 17.97 3.84 .59 1.65 2.32 2.49 2.42 93.4
D19S180 1.65 (.154) 5.13 1.10 .08 1.16 1.55 1.65 1.60 ?
D19S210 1.08 (.259) 20.89 8.79 4.47 1.14 .13 .71 .98 104.9
a LOD scores were calculated under an autosomal dominant mode of inheritance, a penetrance of 90%, and a phenocopy rate of 0.
b Distances from 19pter and the order of loci are from maps reported by Gyapay et al. (1994), Ashworth et al. (1995), and the Whitehead
Institute for Biomedical Research/MIT Center for Genome Research. A question mark (?) indicates that the distance is unknown.
10 ml containing 50 ng genomic DNA, 20 ng each primer,
0.5 U Taq polymerase, and the recommended PCR buf-
fer, which included 1–3 mM MgCl2, for 24–35 cycles
under conditions described previously (Pearce et al.
1995, 1996a; Lloyd et al. 1996; The European Con-
sortium on MEN1 1997). Reactions for individuals were
either multiplexed or multipooled, as appropriate for the
PCR conditions (Reed et al. 1994), allele sizes, and fluo-
rescent label. Alleles were detected on a 6% denaturing
polyacrylamide gel (12-cm well-to-read plates), by use
of a semiautomated DNA fragment analyzer (ABI 377)
and GENESCAN software (The European Consortium
on MEN1 1997). Alleles were scored directly by use
of the GENOTYPER program. Two-point LOD scores
were calculated by use of the MLINK and ILINK pro-
grams (Thakker et al. 1990), with the frequency and
penetrance of FBHOk set at 10
4 and 90%, respectively
(Trump et al. 1995); variation of these values had no
significant effect on the results of the linkage analysis.
DNA Sequence Analysis of Calmodulin (CALM) III
CALM III–specific primers (details available on re-
quest) were designed from the published sequence (Kol-
ler et al. 1990) and were used for PCR amplification of
the six exons and their splice sites, all of the 123-bp 5′
UTR and 238 bp of the upstream promoter region that
contains minor transcriptional sites, and 68 bp of the
1,621-bp 3′ UTR. The size of each CALM III exon is as
follows: exon 1, 126 bp; exon 2, 31 bp; exon 3, 144
bp; exon 4, 107 bp; exon 5, 136 bp; and exon 6, 1,650
bp (Koller et al. 1990). The first 123 bp of exon 1 consist
of the 5′ UTR, and the initiator methionine is encoded
by 124–126 bp. The remaining 147 amino acids of the
148–amino acid CALM III are encoded by exons 2–5
and the 5′ 29 bp of exon 6. The proximity of exons 5
and 6 made it feasible to amplify their coding regions
together with intron 5, with one set of primer pairs.
Thus, the sizes of the PCR products that contained the
promoter region, 5′ UTR, and exon 1; exon 2; exon 3;
exon 4; and exon 5, exon 6, and the 68 bp of the 3′
UTR were 419, 300, 285, 313, and 465 bp, respectively.
DNA from an FBHOk-affected member (III-3, fig. 1) and
from an unaffected unrelated individual was used, and
the DNA sequences of the PCR products were deter-
mined as described previously (Pearce et al. 1995, 1996a,
1996c; Lloyd et al. 1996), by use of a semiautomated
system (ABI 373).
Results
We undertook a genomewide linkage search for the
FBHOk locus, using microsatellite-repeat markers spaced
an average of 13 cM apart (Reed et al. 1994). Following
an analysis with 76 polymorphic loci, which consisted
of 12, 14, 16, 11, 6, 4, 6, and 7 loci (details available
on request) from chromosomes 5, 7, 8, 9, 11, 15, 19,
and 21, respectively, linkage was established between
FBHOk and the chromosome 19q locus D19S220, with
a peak LOD score of 4.45 at recombination fraction (v)
.075 (table 1). In addition, the recombinants observed
between FBHOk and the chromosome 19q loci suggested
that FBHOk was located between D19S220 and D19S210
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(fig. 1), an interval estimated to be 43.5 cM (ta-
ble 1). Therefore, eleven additional polymorphic loci
(D19S913, D19S908, D19S412, D19S219, D19S606,
D19S902, D19S879, D19S604, D19S866, D19S907,
and D19S572) from this interval were used (Gyapay et
al. 1994; Ashworth et al. 1995) for further studies.
Linkage between FBHOk and eight polymorphic loci—
D19S220, D19S913, D19S908, D19S219, D19S606,
D19S902, D19S879, and D19S604—was established
(table 1), with peak LOD scores of 3.27–6.67 (v 
–.093). Thus, FBHOk was mapped to chromosome.000
19q13. An analysis of recombinants helped to further
localize FBHOk. The pedigree in figure 1 shows 43 mem-
bers (41 surviving and 2 deceased), from four genera-
tions, with data from 12 chromosome 19q13 microsat-
ellite polymorphic loci. The haplotype of individual I-1,
a deceased affected father, was ascertained by an ex-
amination of his four affected children (II-2, II-4, II-6,
and II-9) and one unaffected son (II-7). His affected
daughter, II-2, inherited a recombinant haplotype that
locates FBHOk centromeric to D19S866. Her affected
son, III-4, inherited a recombinant haplotype that locates
FBHOk telomeric to D19S908. The combined observa-
tions of the recombinants observed in II-2 and III-4 lo-
cate FBHOk within the !12-cM interval (table 1) flanked
centromerically by D19S908 and telomerically by
D19S866.
A survey of human–chromosome 19 maps (Lawrence
Livermore National Laboratory) and of human-gene da-
tabases (Genome Database and Genbank) revealed that
the gene encoding CALM III was located within this
!12-cM interval (Berchtold et al. 1993; Ashworth et al.
1995). CALM is a highly conserved, ubiquitously ex-
pressed, intracellular Ca2-binding protein that is known
to have a function in signal transduction, through its
role as the delta subunit of phosphorylase kinase (Bachs
et al. 1994). There are at least three expressed copies of
CALM in the human genome, with several additional
CALM-like genes and pseudogenes (Berchtold et al.
1993; Rhyner et al. 1994). The three human CALM
genes, referred to as “CALM I,” “CALM II,” and
“CALM III,” each of which contains four calcium-bind-
ing domains, have different sequences in the promoter
regions, suggesting differential regulation at the tran-
scriptional level (Berchtold et al. 1993; Bachs et al. 1994;
Rhyner et al. 1994). The chromosomal location and
functional properties of the CALM III gene, which con-
sists of six exons that span 10 kb of genomic DNA
(Koller et al. 1990), suggested that it may represent a
candidate gene for FBHOk. However, DNA sequence
analysis of the 1,782 bp that encompass the coding re-
gion in the six exons, their consensus splice sites, all of
the 5′ UTR, the 238 bp of the upstream promoter region,
and !5% of the 3′ UTR of CALM III from an individual
affected with FBHOk and from an unrelated normal in-
dividual did not detect any abnormalities, thereby in-
dicating that the CALM III gene is unlikely to be the
gene responsible for FBHOk.
Discussion
Our mapping of FBHOk to chromosome 19q13 and
to the !12-cM interval flanked by D19S908 and
D19S866 represents an important advance in the iden-
tification of this gene, which regulates calcium homeo-
stasis. This gene may possibly encode another CaSR or
a downstream mediator in the CaSR pathway. The CaSR
pathway, which begins with ligand binding by the CaSR,
involves G-protein–dependent stimulation of PLC activ-
ity that causes an accumulation of IP3 and a rapid release
of [Ca2]i from intracellular stores, followed by an influx
of [Ca2]o (Pearce et al. 1996b; Bai et al. 1997; Brown
1997; Hebert et al. 1997). The intermediary between
elevation of [Ca2]i and the physiological response of a
decrease in the rate of PTH secretion from the parathy-
roid cell and a reduction in renal tubular calcium reab-
sorption is likely to involve a type of calcium-binding
protein that may be either a calcium-dependent enzyme
or a calcium-dependent modulating protein such as
CALM (Bachs et al. 1994; Crivici and Ikura 1995;
Gnegy 1995). Our database searches of human–
chromosome 19q13 maps (Lawrence Livermore Na-
tional Laboratory, Genome Database, and Genbank)
and of the syntenic regions on mouse chromosome 7,
for CaSRs and putative mediators, revealed two poten-
tial candidate genes for FBHOk. These were a mouse
CaSR-related sequence, referred to as “Casr-rs1” (Hin-
son et al. 1997), and the human CALM III gene
(Berchtold et al. 1993).
Casr-rs1 is one of five CaSR-related sequences (Casr-
rs1 to Casr-rs5) that have been identified in mice (Hinson
et al. 1997). Casr-rs1 has been located on mouse chro-
mosome 7 and, hence, is in the region syntenic to human
chromosome 19q13. However, our BLAST analysis of
Casr-rs1, which has 40% amino acid identity to the hu-
man CaSR, revealed 81% identity to the mouse pher-
omone receptor VR6 (Matsunami and Buck 1997).
Furthermore, recent analysis of the compact genome of
the fish Fugu rubripes has revealed a large family of
receptors that are closely related to CaSR (Naito et al.
1998). These appear to be the fish homologues of the
vomeronasal receptors, which are GPCRs activated by
some volatile odorant pheromones, reported in mice and
rats (Herrada and Dulac 1997; Matsunami and Buck
1997). However, to date, human homologues of pher-
omone receptors and Casr-rs1 have not been isolated.
Thus, the relationships between these pheromone recep-
tors, Casr-rs1, and the FBHOk gene cannot be defined
and must await the characterization of the human homo-
logues of these fish and mouse receptors.
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The second candidate gene identified for FBHOk en-
coded for a CALM, which is a ubiquitous, intracellular
calcium-binding regulatory protein that is involved in
many signaling pathways (Crivici and Ikura 1995;
Gnegy 1995). Thus, CALM may activate the function
of various kinases (CALM kinases I and II and myosin
light-chain kinase), phosphatases (calcineurin), ion
channels (plasma membrane Ca2 pump), phosphodies-
terase, adenylate cyclase, and nitric oxide synthetase. In
addition, CALM may regulate cell-surface expression of
the integral membrane protein, L-selectin, through a pro-
teolytic mechanism (Kahn et al. 1998). Three human
CALM genes, CALM I, CALM II, and CALM III, have
been identified, and CALM III has been mapped to chro-
mosome 19q13 (Berchtold et al. 1993; Rhyner et al.
1994). The chromosomal location and the likely func-
tional properties of CALM III, on the basis of those of
the other CALMs, indicated it as a strong candidate gene
for FBHOk. However, the absence of CALM III DNA-
sequence abnormalities in an individual with FBHOk in-
dicated that the CALM III gene was unlikely to be im-
plicated in the etiology of this disorder and that other
candidate genes need to be identified.
Our localization of FBHOk to a well-defined region of
chromosome 19q13 represents an important step for the
identification of the basis of this disorder of calcium
homeostasis. The !12-cM interval containing the FBHOk
gene appears to be, on a physical map, as small as 4 Mb
in size, and 130 genes and expressed sequence-tagged
sites have been mapped to this region (Ashworth et al.
1995; Durocher et al. 1995; Lawrence Livermore Na-
tional Laboratory). In addition, the region has been pre-
pared for long-range sequencing (Lawrence Livermore
National Laboratory), and, thus, our mapping of FBHOk
may help in the identification of disease associations and
functional properties of genes isolated from this region.
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